Importer of Controlled Substances Application: Medi-Physics, Inc. dba GE Healthcare, 2456-2457 [2021-00353]
Download as PDF
<![CDATA[
2456
Federal Register / Vol. 86, No. 7 / Tuesday, January 12, 2021 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation Nos. 701–TA–522 and 731–
TA–1258 (Review)]
Passenger Vehicle and Light Truck
Tires From China; Scheduling of
Expedited Five-Year Reviews
United States International
Trade Commission.
ACTION: Notice.
AGENCY:
The Commission hereby gives
notice of the scheduling of expedited
reviews pursuant to the Tariff Act of
1930 (‘‘the Act’’) to determine whether
revocation of the countervailing and
antidumping duty orders on passenger
vehicle and light truck tires from China
would be likely to lead to continuation
or recurrence of material injury within
a reasonably foreseeable time.
DATES: October 5, 2020.
FOR FURTHER INFORMATION CONTACT:
Alejandro Orozco (202–205–3177),
Office of Investigations, U.S.
International Trade Commission, 500 E
Street SW, Washington, DC 20436.
Hearing-impaired persons can obtain
information on this matter by contacting
the Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
these reviews may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov.
SUPPLEMENTARY INFORMATION:
Background.—On October 5, 2020, the
Commission determined that the
domestic interested party group
response to its notice of institution (85
FR 39581, July 1, 2020) of the subject
five-year reviews was adequate and that
the respondent interested party group
response was inadequate. The
Commission did not find any other
circumstances that would warrant
conducting full reviews.1 Accordingly,
the Commission determined that it
would conduct expedited reviews
pursuant to section 751(c)(3) of the
Tariff Act of 1930 (19 U.S.C. 1675(c)(3)).
For further information concerning
the conduct of these reviews and rules
of general application, consult the
Commission’s Rules of Practice and
Procedure, part 201, subparts A and B
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
1 A record of the Commissioners’ votes is
available from the Office of the Secretary and at the
Commission’s website.
VerDate Sep<11>2014
17:09 Jan 11, 2021
Jkt 253001
(19 CFR part 201), and part 207,
subparts A, D, E, and F (19 CFR part
207).
Please note the Secretary’s Office will
accept only electronic filings at this
time. Filings must be made through the
Commission’s Electronic Document
Information System (EDIS, https://
edis.usitc.gov). No in-person paperbased filings or paper copies of any
electronic filings will be accepted until
further notice.
Staff report.—A staff report
containing information concerning the
subject matter of the reviews will be
placed in the nonpublic record on
January 8, 2021, and made available to
persons on the Administrative
Protective Order service list for these
reviews. A public version will be issued
thereafter, pursuant to section
207.62(d)(4) of the Commission’s rules.
Written submissions.—As provided in
section 207.62(d) of the Commission’s
rules, interested parties that are parties
to the reviews and that have provided
individually adequate responses to the
notice of institution,2 and any party
other than an interested party to the
reviews may file written comments with
the Secretary on what determination the
Commission should reach in the
reviews. Comments are due on or before
January 14, 2021 and may not contain
new factual information. Any person
that is neither a party to the five-year
reviews nor an interested party may
submit a brief written statement (which
shall not contain any new factual
information) pertinent to the reviews by
January 14, 2021. However, should the
Department of Commerce (‘‘Commerce’’)
extend the time limit for its completion
of the final results of its reviews, the
deadline for comments (which may not
contain new factual information) on
Commerce’s final results is three
business days after the issuance of
Commerce’s results. If comments
contain business proprietary
information (BPI), they must conform
with the requirements of sections 201.6,
207.3, and 207.7 of the Commission’s
rules. The Commission’s Handbook on
Filing Procedures, available on the
Commission’s website at https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf, elaborates
2 The Commission has found the response to its
notice of institution filed by the United Steel, Paper
and Forestry, Rubber, Manufacturing, Energy,
Allied Industrial and Service Workers International
Union (‘‘domestic interested party’’), which
represents workers at five domestic producers of
PVLT tires: Cooper Tire & Rubber Company, the
Goodyear Tire & Rubber Company, Michelin North
America Inc., Sumitomo Rubber USA, LLC, and the
Yokohama Rubber Co., Ltd., to be adequate.
Comments from other interested parties will not be
accepted (see 19 CFR 207.62(d)(2)).
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
upon the Commission’s procedures with
respect to filings.
In accordance with sections 201.16(c)
and 207.3 of the rules, each document
filed by a party to the reviews must be
served on all other parties to the review
(as identified by either the public or BPI
service list), and a certificate of service
must be timely filed. The Secretary will
not accept a document for filing without
a certificate of service.
Determination.—The Commission has
determined these reviews are
extraordinarily complicated and
therefore has determined to exercise its
authority to extend the review period by
up to 90 days pursuant to 19 U.S.C.
1675(c)(5)(B).
Authority: These reviews are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.62 of the
Commission’s rules.
By order of the Commission.
Issued: January 7, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–00435 Filed 1–11–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–763]
Importer of Controlled Substances
Application: Medi-Physics, Inc. dba GE
Healthcare
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Medi-Physics, Inc. dba GE
Healthcare has applied to be registered
as an importer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before February 11, 2021. Such
persons may also file a written request
for a hearing on the application on or
before February 11, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
SUMMARY:
E:\FR\FM\12JAN1.SGM
12JAN1
2457
Federal Register / Vol. 86, No. 7 / Tuesday, January 12, 2021 / Notices
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on December 15, 2020,
Medi-Physics, Inc. dba GE Healthcare,
3350 North Ridge Avenue, Arlington
Heights, Illinois 60004–1412, applied to
be registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Cocaine ........................
Drug
code
9041
Schedule
II
The company plans to import small
quantities of Ioflupane, in the form of
three separate analogues of Cocaine, to
validate production and quality control
systems, for a reference standard, and
for producing material for a future
investigational new drug submission.
Supplies of this particular controlled
substance are not available in the form
needed within the current domestic
supply of the United States. No other
activity for this drug code is authorized
for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–00353 Filed 1–11–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–756]
Bulk Manufacturer of Controlled
Substances Application: Cedarburg
Pharmaceuticals
William T. McDermott,
Assistant Administrator.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
[FR Doc. 2021–00351 Filed 1–11–21; 8:45 am]
Cedarburg Pharmaceuticals
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 15, 2021. Such persons
may also file a written request for a
hearing on the application on or before
March 15, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on October 16, 2020,
Cedarburg Pharmaceuticals 870 Badger
Circle, Grafton, Wisconsin 53024,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUMMARY:
Controlled substance
Tetrahydrocannabinols
3, 4Methylenedioxymethamphetamine.
Dimethyltryptamine .......
Psilocybin .....................
Methylphenidate ...........
Nabilone .......................
4-Anilino-N-phenethyl-4piperidine (ANPP).
Fentanyl ........................
Drug
code
The company plans to manufacture
bulk active pharmaceutical ingredients
(API) for distribution to its customers. In
reference to the drug code 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture as synthetic.
No other activity for this drug code is
authorized for this registration.
Schedule
7370
7405
I
I
7435
7437
1724
7379
8333
I
I
II
II
II
9801
II
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–765]
Bulk Manufacturer of Controlled
Substances Application: Organix, Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Organix, Inc. has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 15, 2021. Such persons
may also file a written request for a
hearing on the application on or before
March 15, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on September 22, 2020,
Organix, Inc., 240 Salem Street,
Woburn, Massachusetts 01801, applied
to be registered as an bulk manufacturer
of the following basic class(es) of
controlled substance(s):
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Controlled substance
Drug code
Gamma Hydroxybutyric Acid ...........................................................................................................................................
Lysergic acid diethylamide ..............................................................................................................................................
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine .................................................................................................................................
Bufotenine ........................................................................................................................................................................
Dimethyltryptamine ..........................................................................................................................................................
Psilocybin .........................................................................................................................................................................
Psilocyn ...........................................................................................................................................................................
Heroin ..............................................................................................................................................................................
VerDate Sep<11>2014
18:51 Jan 11, 2021
Jkt 253001
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
E:\FR\FM\12JAN1.SGM
12JAN1
2010
7315
7360
7370
7431
7433
7435
7437
7438
9200
Schedule
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 86, Number 7 (Tuesday, January 12, 2021)]
[Notices]
[Pages 2456-2457]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-00353]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-763]
Importer of Controlled Substances Application: Medi-Physics, Inc.
dba GE Healthcare
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Medi-Physics, Inc. dba GE Healthcare has applied to be
registered as an importer of basic class(es) of controlled
substance(s). Refer to Supplemental Information listed below for
further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before February 11,
2021. Such persons may also file a written request for a hearing on the
application on or before February 11, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield,
[[Page 2457]]
Virginia 22152. All requests for a hearing should also be sent to: (1)
Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia 22152; and (2) Drug
Enforcement Administration, Attn: DEA Federal Register Representative/
DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on December 15, 2020, Medi-Physics, Inc. dba GE
Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004-
1412, applied to be registered as an importer of the following basic
class(es) of controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Cocaine................................ 9041 II
------------------------------------------------------------------------
The company plans to import small quantities of Ioflupane, in the
form of three separate analogues of Cocaine, to validate production and
quality control systems, for a reference standard, and for producing
material for a future investigational new drug submission. Supplies of
this particular controlled substance are not available in the form
needed within the current domestic supply of the United States. No
other activity for this drug code is authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-00353 Filed 1-11-21; 8:45 am]
BILLING CODE P
